An interventional study of Telemonitoring and Standard-of-care in Atypical Parkinsonism, MSA - Multiple System Atrophy and PSP, sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta. Active, not recruiting at 4 sites in Italy. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Not applicable, Interventional, and Supportive care
This project aims to investigate whether an integrated model based on proactive and reactive telenursing monitoring coordinated by a parkinsonism nurse specialist (case manager) is able to improve care delivery and quality of life of patients with atypical parkinsonisms. This could reduce the risk (e.g. through health education counselling) and the severity of complications (e.g. falls). Main responsibilities of the Co-PI: project idea and supervision, coordination of the study, patient selection and recruitment, patient recruitment, participation in statistical analysis and drafting the manuscript. Co-PI is responsible of the rate of recruitment and drop-out
People with parkinsonism experience a wide range of motor and non-motor disorders associated with the increasing complexity of care delivery and the increased risk of complications with increased hospital access. Although a number of multidisciplinary care models have been proposed so far, results have been disappointing in terms of benefit in quality of life and cost-effectiveness. An integrated remote care model at home, involving a parkinsonism nurse specialist (PKNS) as well as a movement disorder specialist, could offer significant benefits to patients and healthcare professionals through better health education, continuity of care and more careful monitoring of the complications of the accident. In this multicenter, randomized, single-blinded, case-control trial, the investigators will recruit 164 patients with atypical parkinsonism (either MSA or PSP) to investigate the efficacy and cost-effectiveness of a 12-month remote home-based integrated program to improve healthcare delivery, coordinated by a specialized nurse (case manager) compared to standard medical care. This organizational model of personalized medicine aims to simplify, standardize and improve patient care and monitoring over time, including remote management of situations of urgency. This telenursing program consists of both proactive and reactive monitoring approaches acting synergistically to optimize the continuity of care by tertiary expert movement disorders clinics. In proactive monitoring, patients are contacted at baseline (to create a patient record focused on identifying individual-specific vulnerabilities) and then every 3 months. During the 12-month study period, patients and caregivers may contact the case manager in case of any problems (reactive monitoring), who may: (a) deal with the specific problem also by interacting with the participant's general practitioner and other healthcare professionals (e.g. physical therapist, psychologist, nutritionist, occupational therapist, social worker, etc) or (b) refer to the neurologist for teleconsultation or in-person visit according to a semi-structured algorithm, which assigns 4 levels of priority. Participants will be evaluated with clinical scales testing the quality of life, motor and non-motor symptoms, caregiver burden, adherence to therapy, cumulative disease burden and the number of unscheduled hospital access during the study period. The cost-effectiveness of this method will also be evaluated by using the EuroQoL, which will estimate the incremental cost per quality-adjusted life-years (QALY) gain. Finally, the investigators will assess the feasibility and utility of Telemonitoring to guide decisionmaking by using a waist-worn wearable (STAT-ONTM) to monitor real-life motor autonomy and the risk of falls, including freezing of gait for 5 consecutive days every month during the 12-month duration of the study. If successful, this low-cost integrated management of patients with atypical parkinsonism may be extended to people with the more prevalent Parkinson's disease as well as other neurodegenerative disorders (e.g. Alzheimer's dementia)
135 studies on the registry are indexed under Shy-Drager Syndrome; 34 are open to participants now.
This study's planned enrollment of 164 is above the median of 40 across 85 interventional studies indexed under Shy-Drager Syndrome.
Browse Shy-Drager Syndrome studies →Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta is the lead sponsor of 83 studies on the registry; 32 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients are followed up by a nurse-telemonitoring
Other: Telemonitoring
Patients are followed up only by the neurologist
Other: Standard-of-care
Patients are followed up by a nurse specialist in parkinsonism who interacts with the treating neurologist and a multidisciplinary team
Patients are managed only by the neurologist according the institution's clinical practice
Changes in total score of the Parkinson's Disease Questionnaire 39-items scale (PDQ-39)
Thi is a 39-items questionnaire assessing the quality of life of patient with Parkinsonism. Score is expressed in percentage from 0% to 100%. The higher the score the lower the quality of life
Time frame: baseline, week 52
Changes in the Movement Disorder Society Unified Parkinson's Disease Rating Scale part II (MDS-UPDRS Part II)
This is a scale (MDS-UPDRS Part II) used to assess activities of daily living. Score ranges from 0 to 52. The higher the score the worse the Disability
Time frame: baseline, week 52
Changes in the Movement Disorder Society Unified Parkinson's Disease Rating Scale part IV (MDS-UPDRS part IV)
This is a scale (MDS-UPDRS part IV) used to assess complications of dopaminergic therapy. Score ranges from 0 to 24. The higher the score the worse the disability
Time frame: baseline, week 52
Changes in the Non-Motor Symptoms Scale score (NMSS)
This is a scale used to assess the burden of non-motor symptoms in Parkinson's disease. Total score is 0-360. The higher the score the worse the disability
Time frame: baseline, week 52
Changes in Unified Multiple System Atrophy Rating Scale (UMSARS)
This scale (UMSARS) is used to assess disease progression in multiple system atrophy.The score is from 0 up to 109. The higher the score the worse the disability
Time frame: baseline, week 52
Changes in Progressive Supranuclear Palsy Rating Scale (PSPRS)
This scale (PSPRS) is used to assess disease progression in Progressive Supranuclear Palsy. The total score is 0-100. The higher the score the worse the disability
Time frame: baseline, week 52
Changes in the activities of daily living questionnaire (ADL_questionnaire)
The "ADL (Activities of Daily Living)" evaluation refers to the fundamental activities of daily life in which the subject is dependent: on a scale from 0 to 6 points, the lower the score, the greater the person's need for assistance
Time frame: baseline, week 52
Changes in the intrumental activities of daily living questionnaire (IADL)
The "IADL (Instrumental Activities of Daily Living)" evaluation refers to the instrumental activities of daily life in which the subject is dependent (eg using telephone, preparing meals, taking medications, etc): on a scale from 0 to 8 points, the lower the score, the greater the person's need for assistance
Time frame: baseline, week 52
Changes in the Zarit Burden Interview scale score (ZBI)
This is a scale used to investigate caregiver's burnout. Total score is 0-40. The higher the score the worse the disability
Time frame: baseline, week 52
Number of unplanned hospital admission
Sum of number of outpatients departments assessments, number of emergency rooms accesses, number of unplanned hospitalizations
Time frame: week 52
Number of incident comorbidities
The number of incident comorbidities over the 12.month study period will be assessed using a semistructured interview
Time frame: baseline, week 52
Changes in Euro Quality Of Life Dimensions-5 Levels score (EuroQOL-5)
This is a useful and validated instrument to measure quality of life in patients with Parkinson's disease. The patient select a score from 0 to 100. The lowest the score the lowest quality of life.
Time frame: baseline, week 52
Changes in the Morisky Medical Adherence scale-8 items score (MMAS)
This is an 8-items scale used to investigate patient adherence to the therapy prescribed by the MD specialist. Score is 0-8 "yes" answer. The 3 categorical Likert Scale is: low adherence \<6; medium adherence 6-8; high adherence 8.
Time frame: baseline, week 26, week 52
Changes in patient experience questionnaire (EQ)
This is a questionnaire assessing patient perception and satisfaction of the quality of health care. Total score is 0-100. The highest the score, the worst the satisfaction
Time frame: baseline, week 26, week 52
Changes in freezing of walking, Freezing of gait-questionnaire (FOG-Q)
Changes in gait performances, mainly in freezing of walking, are analysis by this questionnaire. Total score is 0-24. The highest the score, the highest the freezing
Time frame: baseline, week 52
Plan to share: Yes — Data obtained through this study may be provided to qualified researchers with academic interest on this topic. Data shared will be coded, with no protected health information included. Approval of the request and execution of all applicable agreements are prerequisites to the sharing of data with the requesting party
Supporting information: Study protocol, Sap, Csr
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta